Clinical Trial Update: A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 pharmacokinetics/dynamics study of F-627 in women with neutropenia undergoing myelotoxic chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• F-627

Snippet

Sponsor: EVIVE Biotechnology | Conditions: Neutropenia | Phase 1, Phase 2 | Status: COMPLETED